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Abstract
Background: PCSK9 inhibitor therapy has been approved by the FDA as an adjunct to diet-maximal tolerated
cholesterol lowering drug therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical
atherosclerotic cardiovascular disease (ASCVD) with suboptimal LDL cholesterol (LDLC) lowering despite maximal
diet-drug therapy. With an estimated ~24million of US hypercholesterolemic patients potentially eligible for PCSK9
inhibitors, costing ~ $14,300/patient/year, it is important to assess health-care savings arising from PCSK9 inhibitors
vs ASCVD cost.
Methods: In 103 patients with HeFH, and/or ASCVD and/or suboptimal LDLC lowering despite maximally tolerated
diet-drug therapy, we assessed pharmacoeconomics of PCSK9 inhibitor therapy with lowering of LDLC. For HeFH
diagnosis, we applied Simon Broome’s or WHO Dutch Lipid Criteria (score >8). Estimates of direct and indirect costs
for ASCVD events were calculated using American Heart Association (AHA), U.S. DHHS, Healthcare Bluebook, and
BMC Health Services Research databases. We used the ACC/AHA 10-year ASCVD risk calculator to estimate 10-year
ASCVD risk and estimated corresponding direct and indirect costs. Assuming a 50 % reduction in ASCVD events on
PCSK9 inhibitors, we calculated direct and indirect health-care savings.
Results: We started 103 patients (58 [56 %] women and 45 [44 %] men), on either alirocumab (62 %) or
evolocumab (38 %), median age 63, BMI 29.0, and LDLC 149 mg/dl. Of the 103 patients, 28 had both HeFH and
ASCVD, 33 with only ASCVD, 33 with only HeFH, and 9 had neither. Of the 103 patients, 61 had a first ASCVD event
at median age 55 and on best tolerated cholesterol-lowering therapy median LDLC was 137 mg/dl. In these 61
patients, total direct costs attributable to ASCVD were $8,904,361 ($4,328,623 direct, $4,575,738 indirect), the median
10-year risk of a new CVD event was calculated to be 13.1 % with total cost $1,654,758. Assuming a 50 % reduction
in ASCVD events on PCSK9 inhibitors in our 61 patients, $4,452,180 would have been saved in the past; and future
10-year savings would be $1,123,345.
Conclusion: In the 61 CVD patients, net costs/patient/year were estimated to be $7,000 in the past, with future
10-year intervention net costs/patient/year being $12,459, both below the $50,000/year quality adjusted life-year
gained by PCSK9 inhibitor therapy.
(Continued on next page)
* Correspondence: prshah06@gmail.com
Supported by Lipoprotein Research Fund; Jewish Hospital of Cincinnati
From the Cholesterol, Metabolism, and Thrombosis Center, Jewish Hospital
of Cincinnati, Cincinnati, USA
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shah et al. Lipids in Health and Disease  (2016) 15:132 
DOI 10.1186/s12944-016-0302-8
(Continued from previous page)
Keywords: PCSK9, Evolocumab, Alirocumab, Cholesterol, Lipids, Pharmacoeconomics, Heterozygous familial
hypercholesterolemia (HeFH), Cardiovascular disease (CVD)
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, Atherosclerotic
Cardiovascular Disease; BMI, Body Mass Index; CVD, Cardiovascular Disease; FDA, Food and Drug Administration;
HDLC, High Density Lipoprotein Cholesterol; HeFH, Heterozgyous Familial Hypercholesterolemia;
HoFH, Homozgyous Familial Hypercholesterolemia; LDLC, Low Density Lipoprotein Cholesterol; PVLE, Present Value
Life Time Earnings; TC, Total Cholesterol; TG, Triglycerides
Background
Many patients with elevated LDLC fail to achieve treat-
ment targets [1–3], because of statin intolerance [4, 5],
expense, lack of insurance coverage, or variations in
statin availability across states in insurance, race, and
ethnicity [1]. With LDLC lowering potency well beyond
statins, PCSK9 inhibitors now offer the promise of
optimizing LDLC in a majority of patients with hetero-
zygous familial hypercholesterolemia (HeFH), cardio-
vascular disease (CVD), and statin intolerance [6–11].
The PCSK9 inhibitor class of medications allows patients
to attain LDLC levels that were previously unattainable
with maximal diet-drug regimens [6, 10–13]. Preliminary
controlled clinical trials, though not powered to assess
cardiovascular outcomes, showed approximately a 50 %
risk reduction in cardiovascular events [14, 15].
Whether and to what degree health care insurers will
facilitate approval of PCSK9 class of medications [11, 14,
16] at an annual price of $14,000–14,600 per patient
may ultimately be determined by the outcomes of
placebo-controlled trials of hard CVD endpoints and all-
cause mortality [13] or surrogate CVD endpoints such
as regression or non-progression of atherosclerosis by
intravascular ultrasound. Overall costs to society also
need to include analysis of any potential adverse effects
arising from PCSK9 inhibitor use.
Of 734 patients referred to our Cholesterol Center for
diagnosis and treatment of high LDLC and/or CVD,
with LDLC ≥70 mg/dl despite maximally tolerated
cholesterol lowering therapy, we recently reported [17]
that 30 % were eligible by FDA [18] and insurance
carrier criteria for PCSK9 inhibitor therapy [11, 14, 18].
In the general population of the US [19], the CDC re-
cently reported that 36.7 % (78 million) adults (>21 years)
were eligible for cholesterol-lowering medication, but
only 55 % were taking a cholesterol lowering medication
of whom ~90 % were taking a statin. If 30 % of the 78
million hypercholesterolemic adults in the general US
population [19] were, as in our study of hypercholester-
olemic subjects [17], eligible by FDA [18] and insurance
carrier criteria for PCSK9 therapy, this would include
~11 % of the adult population or 23.4 million adults.
Given current pricing of $14,000–14,600 per patient
per year, annual United States PCSK9 inhibitor costs
might approximate $185–$342 billion, reflecting the use
of an expensive specialty drug for endemic CVD, the
leading cause of mortality in the USA [20, 21]. In 2011,
annual costs for CVD and stroke were estimated to be
$320.1 billion [22]. If, speculatively, CVD and stroke in-
cidence could be halved by PCSK9 therapy [11, 14, 16],
direct annual savings would be estimated to be $160
billion, and indirect annual savings might be $85 billion
[21], altogether $245 billion savings, in the middle of the
range of estimated PCSK9 inhibitor costs of $185–342
billion [17]. Programs targeted to prevention of CVD
should provide substantial overall cost savings [23, 24].
Answers are needed for major questions regarding
PCSK9 inhibitor therapy including whether the PCSK9 in-
hibitors will significantly reduce morbid and mortal CVD
events in hypercholesterolemic patients beyond the best
currently available diet-statin therapy [25], and whether
they will provide an incremental cost-effectiveness ratio
[25] within a society willingness-to-pay threshold [26].
In 103 hypercholesterolemic patients, 61 with previous
CVD (1st CVD median age 55, median LDLC 139 mg/dl
despite maximal tolerated cholesterol-lowering therapy),
we estimated direct + indirect costs of CVD, costs of es-
timated next 10 year CVD events, and PCSK9 inhibitor
costs to assess whether PCSK9s would provide an incre-
mental cost-effectiveness ratio [25] within a society
willingness-to-pay threshold [26].
Methods
The procedures were in accordance with the ethical
standards of the responsible committee on human ex-
perimentation, approved by the Jewish Hospital Institu-
tional Review Board. The study was carried out with
signed informed consent.
Since the commercialization of PCSK9 inhibitors, starting
July 2015, we have started 103 patients on either alirocu-
mab or evolocumab. When considering PCSK9 inhibitor
therapy, we had two groups of patients based on FDA and
insurance criteria with suboptimal LDLC lowering. The
first group of patients (n = 31) were those who were on
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“maximal-tolerated statin therapy,” and also maximum
tolerated cholesterol lowering therapy (i.e., colesevelam
and/or ezetimibe). The second group of patients (n = 72)
were those who couldn’t tolerate ANY dose of two or more
statins and were on maximal tolerated dose of colesevelam
and/or ezetimibe. “Maximal tolerated statin therapy”
includes not being able to tolerate any statin dose level.
In the 103 patients, we assessed the number approved
for coverage either through commercial insurance or
Medicare/Medicaid. We further characterized the approved
patients based on meeting indications such as HeFH,
homozygous familial hypercholesterolemia (HoFH), and/or
CVD or none of the above.
In order to assess for HeFH, we applied Simon Broome’s
[27] or WHO Dutch Lipid Criteria [28] (score >8) for
HeFH by tendon xanthomas and LDLC >190 mg/dl and/
or family history of premature cardiovascular disease and/
or family history of severe hypercholesterolemia.
At the time of PCSK9 insurance coverage application,
before starting PCSK9 therapy, we assessed the following
patient characteristics: type and dose of PCSK9 therapy to
be started, lipids and lipoprotein cholesterol levels on
maximally tolerated diet and lipid lowering drugs, age,
gender, BMI (body mass index), previous and current chol-
esterol lowering therapies, and CVD event age, if applicable.
Within the CVD events group, we documented coronary
artery disease, acute myocardial infarction, cerebrovascular
accidents/stroke, carotid artery disease, and heart failure.
For the 61 patients who had a CVD event, the associ-
ated direct and indirect costs before starting PCSK9
therapy were calculated using U.S. Department of Health
and Human Services, BMC Health Services Research,
and Healthcare Bluebook databases [29–31]. For direct
cost calculations, we categorized CVD patients into hav-
ing coronary artery disease, acute myocardial infarction,
stroke/acute cerebrovascular disease, and/or congestive
heart failure and calculated average hospitalization costs
as per HCUP projections [46]. In our direct cost estima-
tions, we also included the average cost of coronary
artery bypass graft, percutaneous angioplasty, carotid
endartectomy, and follow-up costs for cardiac diagnostic
tests (EKG, stress test, Calcium score), office visits, and
cardiac rehabilitation [32]. For indirect costs calcula-
tions, we used work absenteeism and short term disabil-
ity productivity losses over the years after first CVD
event [29]. We also applied the present value of lifetime
earnings (PVLE) model to calculate indirect costs from
premature mortality within the US in our patients based
on their age group [33]. We estimated savings in PVLE
on PCSK9 using the PCSK9 inhibitor mortality data
from Navarese et al. [34].
We used the ACC/AHA 10 year cardiovascular
disease risk calculator [35] to estimate likelihood of
CVD events within next 10 years, in relevance to the
hypercholesterolemic population. A broad cost and
benefit to society analysis was done using AHA data-
bases [21, 22].
Results
To date we have started 103 patients on either alirocumab
(62 %) or evolocumab (38 %). Table 1 displays characteris-
tics of this cohort of 103 patients, 58 (56 %) women and
Table 1 Characteristics of 103 patients started on PCSK9 inhibitor therapy







Age BMI TC TG HDLC LDLC
All, N = 103 B 15 (15 %); W 88
F 58 (56 %); M 45
73 (71 %) 64 (62 %) P
39 (38 %) R
62 ± 10, 63 29.6 ± 5.4, 29 250 ± 59, 246 165 ± 86, 142 53 ± 16, 53 166 ± 55, 149
CVD, n = 61
1st CVD
age 54 ± 11, 55
B8 (13 %); W 53
F 29 (48 %); M 32
39 (64 %) 42 (69 %) P
19 (31 %) R




age 53 ± 12, 55
B 7 (25 %); W 21
F 19 (68 %); M 9
16 (57 %) 18 (64 %) P
10 (36 %) R




age 55 ± 11, 56
B 1 (3 %); W 32
F 10 (30 %); M23
23 (70 %) 24 (73 %) P
9 (27 %) R
65 ± 10, 66 28.8 ± 4.6, 28.7 205 ± 33, 211 177 ± 113, 147 49 ± 17, 47 123 ± 26, 132
No CVD, n = 42 B 7 (17 %), W 35
F 29 (69 %); M 13
34 (81 %) 22 (52 %) P
20 (48 %) R
59 ± 11, 59 29.1 ± 5.9, 28.6 272 ± 56, 256 159 ± 66, 155 55 ± 14, 56 187 ± 53, 181
HeFH, no CVD,
n = 33
B 4 (12 %), W 29
F 22 (67 %); M 11
26 (79 %) 18 (55 %) P
15 (45 %) R




B 3 (33 %); W6
F 7 (78 %); M 2
8 (89 %) 4 (44 %) P
5 (56 %) R
63 ± 13, 64 29.9 ± 7.0, 29.0 231 ± 15, 233 137 ± 48, 154 56 ± 13, 55 148 ± 17, 149
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45 (44 %) men, with median entry age 63, BMI 29.0, and
mean ± SD LDLC 166 ± 55 mg/dl (median 149). Of the
103 patients, 61 had cardiac disease and/or stroke-TIAs
during past 10 ± 9 years without PCSK9 therapy, Table 1.
Of the 61 patients with cardio-cerebrovascular disease
(CVD), 28 had both HeFH and CVD, and 33 had CVD
without HeFH, Table 1. Of the 42 patients without CVD,
33 had HeFH only, and 9 had neither, Table 1.
In the 103 patients, mean ± SD 10-year CVD risk
calculated from the AHA/ACC calculator was 14.1 ±
12.3 %, median 11.3 % (Table 2). In the 61 patients who
had sustained a cardiac disease and/or stroke-TIAs
before study entry, 10-year calculated CVD risk was
15.9 ± 11.7 %, median 13.1 %. In the 42 patients who had
no CVD at study entry, the next 10 year calculated CVD
risk was 11.5 ± 12.8 %, median 6.8 %.
Follow-up lipid and lipoprotein cholesterol levels at
4 weeks on PCSK9 inhibitor therapy, along with diet
were available for 94 of the 103 patients and for 56 of
the 61 patients with CVD events. Median LDLC in the
94 patients fell from 152 mg/dl (on maximal tolerated
cholesterol lowering therapy without PCSK9 addition) to
76 mg/dl, with the median decrement of LDLC on
therapy of 79 mg/dl, percent LDLC drop from baseline
54 % (median) (Table 3). In the 56 patients with CVD
disease before study entry, median LDLC fell from
141 mg/dl at entry to 60 mg/dl, with a median absolute
reduction of LDLC by 79 mg/dl, median percent LDLC
reduction of 57 % (Table 3). PCSK9 therapy led to a
decrement in triglyceride from median 138 mg/dl to
115 mg/dl, and an increment in HDLC from median
51 mg/dl to 53 mg/dl, Table 3.
Of the 103 patients, 61 had a first CVD event at
median age of 55 years and median LDLC 139 mg/dl
despite maximal tolerated, non-PCSK9 cholesterol-
lowering therapy, Table 1. As displayed in Fig. 1 (top
panel), In the 61 patients with CVD events in the past
10 ± 9 years, total direct costs were $4,328,623, with esti-
mated total indirect costs $4,575,738, with total cost
$8,904,361. For the 61 patients already having had CVD,
future 10-year CVD risk was 15.9 ± 11.7 %, median
13.1 %, calculated using the ACC/AHA calculator
(which does not depend on subject’s CVD event history),
Table 2. Without PCSK9, expected CVD events in these
61 patients in the next 10 years were estimated to cost
$1,654,758, Fig. 1 (top panel), assuming healthcare costs
were to stay the same as current.
Using the human capital approach of Menzin et al.,
[33] we estimated productivity costs as the present value
of lifetime earnings (PVLE) lost due to premature mor-
tality, Fig. 1. As displayed in Fig. 1 (top panel), estimated
costs of PVLE in the next 10 years in the 61 patients
who had already sustained a CVD event was $712,351
without PCSK9 inhibitor therapy. Using PCSK9 inhibi-
tors mortality data by Navarese et al. [34], we estimated
savings in PVLE on PCSK9 in the next 10 years of
$295,966, Fig. 1 (bottom panel).
Mendelian randomization studies suggest that a lifetime
reduction of LDLC~ 40 mg/dl would reduce risk of
ASCVD by 50 % [36]. In our study, after 4 weeks therapy
with PCSK9 inhibitors, and beyond maximally tolerated
LDLC reduction with diet-statins, median LDLC reduction
in the 61 patients with entry CVD was 79 mg/dl, a 57 %
reduction (median) from baseline, Table 3. If PCSK9 inhibi-
tors would have reduced ASCVD event rates in the 61
patients with CVD by 50 %, $4,452,180 would have been
saved (Fig. 1, bottom panel). If PCSK9 inhibitors were used
in the next 10 years, assuming a 50 % reduction in CVD
events, savings from the 10 year projected CVD cost would
be $827,379, in addition to the estimated savings by redu-
cing lost PVLE $295,966, Fig. 1, bottom panel.
In the 61 patients with CVD, PCSK9 therapy costs for
1 year were estimated to be $872,300, Fig. 2. If PCSK9
inhibitor therapy had been used in the past, average
savings for these 61 patients due to CVD event rates
being halved were estimated to be $445,218 for 1 year
(Fig. 2). Net costs for the 61 patients with CVD, were
estimated to be $427,082 for 1 year, and net costs per
patient per year were estimated to be $7,000 (Fig. 2).
Examining 10 years forward for the 61 patients with
CVD before entry, PCSK9 costs for the 61 patients for
1 year were $872,300, Fig. 3. Average annual savings for
61 patients based on halving the estimated 10-year risk
of CVD were estimated to be $82,738, and annual
savings from otherwise lost PVLE were calculated to be
$29,596, Fig. 3. As displayed in Fig. 3, for our 61 patients
with previous CVD events, adding estimated savings of
reduced CVD events (from the ACC/AHA calculator)
Table 2 Estimateda 10 year risk of developing a cardiovascular disease (%)
Mean ± SD % Percentiles
10th 25th 50th 75th 90th
All 103 patients 14.1 ± 12.3 2.0 5.0 11.3 20.5 27.4
61 patients had CVD event pre study 15.9 ± 11.7 3.5 7.2 13.1 21.4 27.4
Years since 1st CVD event in the 61 patients 10.3 ± 8.9 1.4 2.9 8.2 16.3 19.5
42 patients had no CVD 11.5 ± 12.8 1.8 3.4 6.8 18.0 21.6
aEstimated using the ACC/AHA calculator
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and from PVLE, the net cost of PCSK9 therapy was
calculated to be $12,459 per patient per year, Table 3.
Discussion
In the current study, we assessed whether and to what
degree PCSK9 inhibitors, as currently priced, would
provide an incremental cost-effectiveness ratio (ICER)
within a society willingness-to-pay threshold [25, 26],
prolonging life, and representing a societal acceptable
value. In our 61 patients with CVD at entry, the net cost
of PCSK9 inhibitor therapy, assuming a 50 % reduction
of CVD events on PCSK9 inhibitor therapy was $7,000
per patient, and the net cost of PCSK9 therapy over the
next 10 year period was estimated to be $12,459 per
patient per year, well below the $50,000 per year [26] of
life saved which has been used to judge value of a
pharmacologic therapy. Currently, there is no acceptable
model for direct costs of all-cause mortality. Our current
ICER shows $7,000 with CVD reduction of 50 %. If it is
assumed that on top of CVD reduction of 50 %,
all-cause mortality [34] was reduced such that there was
30 % increased savings, then ICER would be $4900 and
if it was reduced by 60 % then ICER would be $2800.
In human health-economics there are two major
approaches: the human capital approach, and the friction
cost method [37–40]. The friction cost method includes
all lost productivity costs due to disease mortality
only until the deceased worker is replaced by an un-
employed worker [41]. The human capital approach is
more widely accepted and recommended as it assumes
Fig. 1 Top Panel: Total, direct, and indirect costs, expected CVD costs for the next 10 years, and loss of present value of lifetime earnings (PVLE),
and costs of PCSK9 inhibitor therapy in 61 hypercholesterolemic patients who had sustained a cardiovascular event (CVD) in the past 10 ± 9 years.
Bottom Panel: Assume PCSK9 inhibitor therapy was used and reduced CVD events by 50 % and lowered PVLE loss
Table 3 Follow-up lipid and lipoprotein cholesterol levels after 4 weeks on PCSK9 inhibitor therapy, mean ± SD [median]
Lipids mg/dl Pre-treatment After 4 weeks on
PCSK9 inhibitor
Change (mg/dl) % change p (paired
Wilcoxon test)
Of 103 patients, 94 at 4 weeks
follow up
TC 251 ± 59 [249] 158 ± 49 [159] −93 ± 54 [−82] −36 ± 18 % [−36 %] <.0001
TG 163 ± 85 [140] 125 ± 48 [119] −38 ± 70 [−24] −16 ± 30 % [−18 %] <.0001
HDLC 54 ± 16 [54] 57 ± 17 [55] +2 ± 9 [+2] +6 ± 15 % [+4 %] .0005
LDLC 166 ± 55 [152] 77 ± 43 [76] −89 ± 50 [−79] −52 ± 23 % [−54 %] <.0001
Of 61 patients with CVD pre
study, 56 at 4 weeks follow up
TC 235 ± 56 [230] 148 ± 46 [146] −88 ± 52 [−80] −36 ± 19 % [−37 %] <.0001
TG 163 ± 97 [138] 118 ± 45 [115] −44 ± 79 [−31] −18 ± 29 % [−20 %] <.0001
HDLC 54 ± 18 [51] 57 ± 19 [53] +3 ± 10 [+2] +7 ± 17 % [+5 %] .002
LDLC 151 ± 51 [141] 68 ± 39 [60] −83 ± 46 [−79] −54 ± 24 % [−57 %] <.0001
Shah et al. Lipids in Health and Disease  (2016) 15:132 Page 5 of 9
no unemployment, captures all lost productivity due to
disease mortality by assuming individuals who died
prematurely would have worked full time until the end
of their working lives, and includes unpaid labor, such as
household work [42–45]. We have used the human
capital approach using the model called present value of
lifetime earnings (PVLE) to estimate indirect costs due
to lost productivity from premature mortality if the
patients were not on PCSK9 therapy [33]. Furthermore,
the model calculates PVLE based on premature mortal-
ity according to age group at death [33]. Presently, direct
costs of all-cause mortality cannot be calculated due to
lack of acceptable model.
Approximately 735,000 people in US have a myocar-
dial infarction and 795,000 have a stroke each year [20].
Heidenreich et al. project that approximately 41 % of the
United States population will have some form of CVD
by 2030 [21]. In the MEGA study involving Pravastatin
10 and 20 mg plus diet with follow-up of 5 years, it was
demonstrated that CVD risk was reduced by 33-35 %.
McConnachie et al. randomized 6,595 hypercholesterol-
emic patients to pravastatin 40 mg or placebo, and
followed them for 15 years [46]. Within five years, in the
pravastatin 40 mg group there was saving of NHS
£710,000 from CVD related direct costs with gain of 136
quality-adjusted life years [46]. In a rosuvastatin vs.
placebo long-term cost effectiveness study with a
hypothetical cohort of 100,000 moderate to high risk
CVD patients with Framingham risk ≥10 %, there was
QALYs (quality-adjusted life-years) gain of 33,480 over
life-time, with 9,916 over 10 years [47]. For a quality-
adjusted life year gained, ICER was $7062 (lifetime) and
$44,466 over 10-years [47]. Montouchet et al. concluded
that in a 1,000 member managed care group, statin treat-
ment to goal with rosuvastatin was cost effective, at an
additional cost per member per month of only $0.007
[48]. Ademi et al. assessed cost of screening for HeFH and
outcomes, assuming a 50 % reduction in events with
statins [49]. The ICER ratio was Australian $4155 per
years of life saved and $3565 per QALY gained [49].
Aljutaili et al. discussed cost-effectiveness of a CHD
preventative program depending on subjects’ risk for CHD,
defined as myocardial infarction, stroke or death. They
concluded that high risk group would benefit by CHD
preventative program (KardioPro) with cost-effectiveness of
€20,901- €26,456 per event-free year [50]. Our per year
Fig. 3 Net cost of PSCK9 inhibitor therapy, based on CVD events estimated from the ACC/AHA risk calculator and present value of lifetime
earnings (PVLE) in 61 patients assuming a 50 % reduction in CVD events and lowered PVLE loss on PCSK9 inhibitor therapy
Fig. 2 Net cost of PCSK9 inhibitor therapy, based on 61 patients’ cost history, assuming a 50 % reduction in CVD events on PCSK9
inhibitor therapy
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cost-effectiveness $7,000 falls in between numbers sug-
gested by Ademi et al. of AUD 4155 (USD 3,117) on
rosuvastatin therapy and Aljutaili et al. of €26,456 (USD
29,101) for high risk/previous CHD event group with all
preventative measures.
Statins have been used for 3 decades or more, with the
CDC estimating that about 55 % of hypercholesterol-
emic patients are taking cholesterol lowering therapy, of
whom ~90 % are taking statins [19]. Consequently, the
American Heart Association estimated that the cost of
CVD was $320.1 billion in 2011; they further estimate
the cost will rise to $1 trillion by 2030 [22]. Given the
rising healthcare cost burden of CVD, which currently
excludes potential savings (as in our current report) of
PCSK9 inhibitor use, both secondary and primary
prevention of CVD [24, 35] will be paramount in the ef-
fort to limit the financial burden of CVD on a growing
society with limited resources.
Many patients with elevated LDLC cannot achieve
treatment targets [1–3] for many reasons [4, 5], while
PCSK9 therapy has been shown to be remarkably effect-
ive beyond the maximal LDLC lowering achieved by
statins [6, 10–13]. In our current study, after maximally
tolerated conventional cholesterol lowering therapy, after
4 weeks on PCKS9 inhibitors, median LDLC was
decreased to median 79 mg/dl (54 % decrease) from
baseline in 103 patients, and was reduced by median
79 mg/dl (57 % decrease) from baseline in the 61
patients with CVD before study entry. Mendelian
randomization studies suggest that an approximate
40 mg/dl drop in LDLC over a lifetime reduces risk of
ASCVD by 50 % [25, 36]. Maintenance of 79 mg/dl
reduction in LDLC observed in the current study should
reduce CVD risk by well over 50 %.
With the introduction of powerful PCSK9 inhibitors,
and as shown in the current study, many patients can
regularly meet LDLC targets, <70 mg/dl for those with
CVD [51], reducing future cardiovascular events by an
estimated 50 % or more. Roth et al. reported 73 %
reduction in LDLC when alirocumab (150 mg given
every 2 weeks) was given with atorvastatin (80 mg daily)
versus atorvastatin (10 mg daily) alone [52]. Alirocumab
ODYSSEY Phase III studies demonstrated that the mean
percentage change in calculated LDLC from baseline to
week 24 beyond statin effect was −61 % (alirocumab)
versus 0.8 % (placebo), p < 0.001 [53]. In 2461 patients
treated with alirocumab, 796 (32 %) had two consecutive
LDLC levels <25 mg/dL while 288 (12 %) had two
consecutive LDLC levels <15 mg/dL [13]. Furthermore,
In the OSLER-1 and OSLER-2 phase III trials, evolocu-
mab reduced LDL cholesterol levels by -61 % at 12-week
on-treatment median [11] beyond statin effect. In a pool
of 2651 evolocumab receiving patients, 1609 (61 %) had
at-least one LDLC <25 mg/dL. Compared to the placebo,
there were minimal adverse reactions to the PCSK9 in-
hibitors with difference between placebo vs. PCSK9 in-
hibitor group consistently <2 % [13].
Statin intolerance, predominantly caused by myalgia,
myositis, and myopathy occurs in 5 % to 20 % of statin-
treated patients [54] who will benefit substantially from
PCSK9 inhibitor therapy [55]. In the GAUSS-3 study,
43 % of patients on atorvastatin had muscle symptoms
and when these patients were enrolled in Phase B, com-
paring ezetimibe plus placebo vs evolocumab plus
placebo, 29 % had myalgias vs 21 % on evolocumab [55].
Furthermore, LDLC reduction from baseline on ezeti-
mibe was 17 vs. 53 % on evolocumab at 24 weeks. In
patients with statin intolerance, evolocumab was well
tolerated and effective [55].
PCSK9 inhibitor therapy is reserved as an adjunct to
diet and maximally tolerated statin therapy for adults
with HeFH or clinical ASCVD requiring additional
lowering of LDLC, at a currently listed cost of $14,000–
14,600/patient/year. The cost to the society of this drug
will rest heavily on the number of people thought to be
at high risk with suboptimal cholesterol lowering despite
maximally tolerated cholesterol lowering therapy with
history of HeFH [56–58] or CVD [59].
Strengths of our study include documented direct
costs of CVD events in hypercholesterolemic patients
with CVD, as well as calculated indirect costs, both for
CVD events in the past, and projected over the forth-
coming 10 years. We have used a PVLE model [33] in
order to estimate indirect cost of premature mortality if
patients were on or not on PCSK9 therapy [34]. This
allowed estimations of net costs per year per patient
with patients meeting FDA drug-candidate criteria, and
receiving PCSK9 inhibitor therapy with either evolocu-
mab or alirocumab. Our direct cost calculations were
limited to average hospital costs of having coronary ar-
tery disease, acute myocardial infarction, stroke/acute
cerebrovascular disease, congestive heart failure, coron-
ary artery bypass graft, percutaneous angioplasty, carotid
endartectomy, and follow-up costs for cardiac diagnostic
tests (EKG, stress test, Calcium score), office visits, and
cardiac rehabilitation. Another limitation of the study in-
volves use of 10 year ACC/AHA risk calculator [35]
which does not include weighting factors for patients
age >80 years, total cholesterol >320 mg/dL, or previous
history of a CVD event. In the current study, we had 61
patients who had previous CVD events, 13 had total
cholesterol >320 mg/dL, and 1 was older than 80 year.
As a group, we speculate that this subcohort’s 10 year
CVD risk was substantially underestimated by the
current estimator. Leening et al. suggest incorporation
of soft ASCVD outcomes such as ischemic heart failure,
transient ischemic attacks (TIAs), angina, and intermit-
tent claudication in calculations of lifetime risks of
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ASCVD, since a large portion of women and younger
individuals suffer from soft ASCVD outcomes [60].
Leening et al. concluded that two-thirds of individuals
will develop some form ASCVD over their life span as
opposed to one-third dying from ASCVD [60].
Conclusions
In the 61 CVD patients in our study, net costs would be
$7,000 /patient/year if PCSK9 had been used in their
past, with a 50 % reduction in CVD event rate. For
PCSK9 intervention for the future 10 years, net costs
were estimated to be $12,459 /patient/year, both below
the $50,000/year quality adjusted life-year a benchmark
for value of care [26]. As currently priced, we project
that PCSK9 inhibitors will provide an incremental cost-
effectiveness ratio within a society willingness-to-pay
threshold [25, 26], prolonging life, and representing a
societal acceptable value.
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